Literature DB >> 24365162

Ligands of the neuropeptide Y Y2 receptor.

Gopi Kumar Mittapalli1, Edward Roberts2.   

Abstract

Neuropeptide Y (NPY) is one of the most abundant neuropeptides in the mammalian brain and exerts a variety of physiological processes in humans via four different receptor subtypes Y1, Y2, Y4 and Y5. Y2 receptor is the most abundant Y subtype receptor in the central nervous system and implicated with food intake, bone formation, affective disorders, alcohol and drugs of abuse, epilepsy, pain, and cancer. The lack of small molecule non-peptidic Y2 receptor modulators suitable as in vivo pharmacological tools hampered the progress to uncover the precise pharmacological role of Y2. Only in recent years, several potent, selective and non-peptidic Y2 antagonists have been discovered providing the tools to validate Y2 receptor as a therapeutic target. This Letter reviews Y2 receptor modulators mainly non-peptidic antagonists and their structure-activity relationships.
Copyright © 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Agonists; Antagonists; Brain-penetration; Neuropeptide Y; Non-peptidic; Structure–activity relationships; Y2 receptor

Mesh:

Substances:

Year:  2013        PMID: 24365162      PMCID: PMC4672871          DOI: 10.1016/j.bmcl.2013.11.061

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  56 in total

1.  BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y(2) receptor antagonist.

Authors:  Y Dumont; A Cadieux; H Doods; L H Pheng; R Abounader; E Hamel; D Jacques; D Regoli; R Quirion
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

2.  BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist.

Authors:  H Doods; W Gaida; H A Wieland; H Dollinger; G Schnorrenberg; F Esser; W Engel; W Eberlein; K Rudolf
Journal:  Eur J Pharmacol       Date:  1999-11-19       Impact factor: 4.432

Review 3.  What is the prognosis for new centrally-acting anti-obesity drugs?

Authors:  David J Heal; Jane Gosden; Sharon L Smith
Journal:  Neuropharmacology       Date:  2012-01-30       Impact factor: 5.250

4.  Chronic administration of the Y2 receptor antagonist, JNJ-31020028, induced anti-depressant like-behaviors in olfactory bulbectomized rat.

Authors:  J C Morales-Medina; Y Dumont; P Bonaventure; R Quirion
Journal:  Neuropeptides       Date:  2012-10-25       Impact factor: 3.286

5.  [(3)H]UR-PLN196: a selective nonpeptide radioligand and insurmountable antagonist for the neuropeptide Y Y(2) receptor.

Authors:  Nikola Pluym; Paul Baumeister; Max Keller; Günther Bernhardt; Armin Buschauer
Journal:  ChemMedChem       Date:  2013-01-29       Impact factor: 3.466

6.  Synthesis and SAR of selective small molecule neuropeptide Y Y2 receptor antagonists.

Authors:  Gopi Kumar Mittapalli; Danielle Vellucci; Jun Yang; Marion Toussaint; Shaun P Brothers; Claes Wahlestedt; Edward Roberts
Journal:  Bioorg Med Chem Lett       Date:  2012-04-30       Impact factor: 2.823

7.  The neuropeptide Y (NPY) Y1 receptor subtype mediates NPY-induced antidepressant-like activity in the mouse forced swimming test.

Authors:  John P Redrobe; Yvan Dumont; Alain Fournier; Rémi Quirion
Journal:  Neuropsychopharmacology       Date:  2002-05       Impact factor: 7.853

8.  Hypothalamic Y2 receptors regulate bone formation.

Authors:  Paul A Baldock; Amanda Sainsbury; Michelle Couzens; Ronaldo F Enriquez; Gethin P Thomas; Edith M Gardiner; Herbert Herzog
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

Review 9.  Neuropeptide Y (NPY) in alcohol intake and dependence.

Authors:  Annika Thorsell
Journal:  Peptides       Date:  2007-01-18       Impact factor: 3.750

10.  The discovery of potent selective NPY Y(2) antagonists.

Authors:  Wenying Chai; Victoria D Wong; Diane Nepomuceno; Pascal Bonaventure; Timothy W Lovenberg; Nicholas I Carruthers
Journal:  Bioorg Med Chem Lett       Date:  2013-05-22       Impact factor: 2.823

View more
  8 in total

Review 1.  Physiological and Therapeutic Roles of Neuropeptide Y on Biological Functions.

Authors:  Pravin Shende; Drashti Desai
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 2.  A novel approach to treating opioid use disorders: Dual agonists of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors.

Authors:  Riley Merkel; Amanda Moreno; Yafang Zhang; Rachel Herman; Jennifer Ben Nathan; Sana Zeb; Suditi Rahematpura; Kamryn Stecyk; Brandon T Milliken; Matthew R Hayes; Robert P Doyle; Heath D Schmidt
Journal:  Neurosci Biobehav Rev       Date:  2021-10-29       Impact factor: 8.989

3.  Neuropeptide Y, a paracrine factor secreted by cancer cells, is an independent regulator of angiogenesis in colon cancer.

Authors:  Debanjan Chakroborty; Sandeep Goswami; Hao Fan; Wendy L Frankel; Sujit Basu; Chandrani Sarkar
Journal:  Br J Cancer       Date:  2022-07-28       Impact factor: 9.075

4.  A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats.

Authors:  Yafang Zhang; Suditi Rahematpura; Kael H Ragnini; Amanda Moreno; Kamryn S Stecyk; Michelle W Kahng; Brandon T Milliken; Matthew R Hayes; Robert P Doyle; Heath D Schmidt
Journal:  Neuropharmacology       Date:  2021-05-11       Impact factor: 5.273

5.  NPY Receptor 2 Mediates NPY Antidepressant Effect in the mPFC of LPS Rat by Suppressing NLRP3 Signaling Pathway.

Authors:  Wenjiao Wang; Tao Xu; Xinyue Chen; Kemeng Dong; Chunkai Du; Jing Sun; Cuige Shi; Xiaoxiao Li; Yutao Yang; Hui Li; Zhi-Qing David Xu
Journal:  Mediators Inflamm       Date:  2019-05-15       Impact factor: 4.711

Review 6.  Neuropeptides Exert Neuroprotective Effects in Alzheimer's Disease.

Authors:  Xin-Yi Chen; Yi-Feng Du; Lei Chen
Journal:  Front Mol Neurosci       Date:  2019-01-11       Impact factor: 5.639

7.  Functional deletion of neuropeptide Y receptors type 2 in local synaptic networks of anteroventral BNST facilitates recall and increases return of fear.

Authors:  Julia Constance Bartsch; Sara Jamil; Dilip Verma; Hans-Christian Pape; Jasmin Remmes
Journal:  Mol Psychiatry       Date:  2020-07-24       Impact factor: 15.992

Review 8.  Ligands of the Neuropeptide Y Y2 Receptors as a Potential Multitarget Therapeutic Approach for the Protection of the Neurovascular Unit Against Acute Ischemia/Reperfusion: View from the Perspective of the Laboratory Bench.

Authors:  Łukasz Przykaza; Ewa Kozniewska
Journal:  Transl Stroke Res       Date:  2021-07-22       Impact factor: 6.829

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.